New chemo combo shows promise against tough breast cancer
NCT ID NCT01525966
First seen Apr 03, 2026 · Last updated May 03, 2026 · Updated 2 times
Summary
This study tested giving two chemotherapy drugs (carboplatin and nab-paclitaxel) before surgery to people with a fast-growing type of breast cancer called triple negative. The goal was to shrink tumors enough so that no cancer remains at the time of surgery. 67 patients with advanced or inflammatory breast cancer took part. The approach aims to improve the chance of a complete response and reduce the amount of tissue that needs to be removed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
City of Hope- South Pasadena Cancer Center
South Pasadena, California, 91030, United States
Conditions
Explore the condition pages connected to this study.